Compare WTBA & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | WTBA | CBIO |
|---|---|---|
| Founded | 1893 | 2003 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.9M | 340.4M |
| IPO Year | 2002 | N/A |
| Metric | WTBA | CBIO |
|---|---|---|
| Price | $23.80 | $14.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $24.00 | ★ $26.67 |
| AVG Volume (30 Days) | 28.1K | ★ 160.9K |
| Earning Date | 04-23-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | ★ 35.21 | N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.69 | N/A |
| Revenue Next Year | $9.18 | $355.04 |
| P/E Ratio | $12.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.33 | $8.72 |
| 52 Week High | $26.60 | $17.39 |
| Indicator | WTBA | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 70.33 |
| Support Level | $23.57 | $11.88 |
| Resistance Level | $24.16 | $15.66 |
| Average True Range (ATR) | 0.72 | 1.13 |
| MACD | 0.05 | 0.29 |
| Stochastic Oscillator | 67.10 | 95.08 |
West Bancorp Inc is a United States-based company that offers a full range of deposit services, including checking, savings and money market accounts and time certificates of deposit. West Bank also offers online banking, mobile banking, and treasury management services, which help to meet the banking needs of its customers. Treasury management services offered to business customers include cash management, client-generated automated clearing house transactions, remote deposit, and fraud protection services. Also offered are merchant credit card processing and corporate credit cards. The bank operates only in the United States of America region.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.